Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab

European Journal of Haematology

Volumn 77, Issue 6, 2006, Pages 527-529

  Gallerani, Elisa ^a   Lerch, Erika ^a   Romagnani, Elena ^a   Stathis, Anastasios ^a   Giardelli, Greta ^a   Zwhalen, Hugo ^b   Marone, Claudio ^b   Cavalli, Franco ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b Ospedale Regionale Bellinzona e Valli   (Switzerland)

Author keywords

Autologous transplantation; Multiple myeloma; Renal failure; Rituximab; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; CASE REPORT; CAUCASIAN; DRUG EFFICACY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MULTIPLE MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; FEMALE; HUMANS; KIDNEY FAILURE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33750631552     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00758.x     Document Type: Article

References (10)

1. ZHENG XL, KAUFMAN RM, GOODNOUGH LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049.
2. ELLIOTT MA, NICHOLS WL JR, PLUMHOFF EA, et al. Post-transplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003;78:421-430.
3. HO VT, CUTLER C, CARTER S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571-575.
4. HOVINGA JA, STUDT JD, ALBERIO L, et al. Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004;41:75-82.
5. HO V, CUTLER C, CARTER S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571-575.
6. VANTELON JM, MUNCK JN, BOURHIS JH, et al. Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. Bone Marrow Transplant 2001;27:531-536.
7. KORNACKER M, LUFT T, HO AD, SCHAEFER HJ. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases. Eur J Haematol 2005;74:250-253.
8. VANTELON JM, MUNCK JN, BOURHIS JH, et al. Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. Bone Marrow Transplant 2001;27:531-536.
9. ROCK G, SHUMAK KH, BUSKARD NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
10. FAKHOURI F, VERNANT JP, VEYRADIER A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-1937.